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Abstract
Background: Beta-catenin is a multifunctional oncogenic protein that contributes fundamentally to cell
development and biology. Elevation in expression and activity of b-catenin has been implicated in many cancers
and associated with poor prognosis. Beta-catenin is degraded in the cytoplasm by glycogen synthase kinase 3 beta
(GSK-3b) through phosphorylation. Cell growth and proliferation is associated with b-catenin translocation from the
cytoplasm into the nucleus.
This laboratory was the first to demonstrate that selenium-containing compounds can enhance the efficacy and
cytotoxicity of anticancer drugs in several preclinical xenograft models. These data provided the basis to identify
mechanism of selenium action focusing on b-catenin as a target. This study was designed to: (1) determine
whether pharmacological doses of methylseleninic acid (MSeA) have inhibitory effects on the level and the onco-
genic activity of b-catenin, (2) investigate the kinetics and the mechanism of b-catenin inhibition, and (3) confirm
that inhibition of b-catenin would lead to enhanced cytotoxicity of standard chemotherapeutic drugs.
Results: In six human cancer cell lines, the inhibition of total and nuclear expression of b-catenin by MSeA was
dose and time dependent. The involvement of GSK-3b in the degradation of b-catenin was cell type dependent
(GSK-3b-dependent in HT-29, whereas GSK-3b-independent in HCT-8). However, the pronounced inhibition of
b-catenin by MSeA was independent of various drug treatments and was not reversed after combination therapy.
Knockout of b-catenin by ShRNA and its inhibition by MSeA yielded similar enhancement of cytotoxicity of
anticancer drugs.
Collectively, the generated data demonstrate that b-catenin is a target of MSeA and its inhibition resulted in
enhanced cytotoxicity of chemotherapeutic drugs.
Conclusions: This study demonstrates that b-catenin, a molecule associated with drug resistance, is a target of
selenium and its inhibition is associated with increased multiple drugs cytotoxicity in various human cancers.
Further, degradation of b-catenin by GSK-3b is not a general mechanism but is cell type dependent.
Background
Beta-catenin protein is a vital component of the canoni-
cal Wnt/b-catenin signaling pathway, which is described
as an oncogenic cause in many human cancers [1]. In
head and neck squamous cell carcinomas (HNSCC), over
expression of the Wnt/b-catenin signaling pathway
increases cell survival and invasion [2]. The higher b-
catenin expression in HNSCC patients, the more
advanced stage [3] and poor prognosis are observed [4].
Mutations in the gene that encodes b-catenin (CTNNB1)
[5] and elevated nuclear b-catenin [6] were implicated in
prostate cancers (CaP).
Over 90% of colorectal cancers (CRC) demonstrate a
deregulated Wnt/b-catenin signaling pathway [7]. Pub-
lished studies suggest that unregulated b-catenin, over-
lapping with adenomatous polyposis coli (APC)
mutation, is associated with the initiation of CRC [8-10].
Beta-catenin is expressed in the cytoplasm and the
nucleus. The cytoplasm b-catenin, as a component of
adherens junctions (AJs) [11], is an essential element of
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cell-to-cell adhesion and stability. The level of cytoplasm
b-catenin is controlled by the activity of a destruction
complex that consists of axin, glycogen synthase kinase
3b (GSK-3b) and APC [12-15]. In the absence of Wnt
signaling, the complex is assembled and GSK-3b
phosphorylates and consequently degrades cytoplasm
b-catenin [14,15]. However, GSK-3b is inactivated in
cancer cells by phosphorylation at serine 9, a similar
mechanism of GSK-3b inhibition by lithium [16,17]. In
the presence of Wnt signaling, b-catenin destruction
complex is disassembled by removing axin [18,19]
resulting in b-catenin accumulation in the cytoplasm.
The accumulated cytoplasm b-catenin hence enters the
nucleus to initiate its oncogenic function. The nuclear
b-catenin has an important function in many human
malignancies [1] by stimulating cell growth and prolif-
eration. The nuclear b-catenin affects TCF/LEF family
transcription factors [20,21] and consequently activates
oncogenes such as cyclin D1 [22,23], Myc [24] and
many other downstream targets. The nuclear accumula-
tion of b-catenin is a critical step in the activation pro-
cess of the canonical Wnt signaling pathway and is
associated with poor prognosis in cancer patients [25].
In addition to its role in cell growth and adhesion,
activated canonical Wnt/b-catenin signaling pathway is
linked to cancer stem cells [26,27] that contribute to
tumor bulk, recurrence and resistance to chemotherapy.
Accordingly, b-catenin inhibitors in combination with
standard systemic therapies hold great promise to
improve treatment’s efficacy and outcome.
The response rates of combination regimen of irinote-
can and 5-fluorouracil/leucovorin (5-FU/LV) is 39% in
metastatic CRC [28]. Treatment with oxaliplatin and 5-
FU/LV has improved the response rate to 50.7% in CRC
[29]. Treatment with docetaxel and prednisone against
metastatic CaP resulted in a median survival of 19.2
months [30]. Docetaxel in combination with cisplatin
and 5-FU against inoperable advanced HNSCC resulted
in a median progression free survival of 11 months [31].
Although the relative survival in advanced solid tumors
is improved by using systemic therapy, the current che-
motherapy cure rates are limited. Thus, the development
of new regimens is greatly needed to achieve a better
clinical outcome.
In our preclinical models, selenium-containing com-
pounds enhanced the efficacy of multiple chemothera-
peutic agents (CPT-11 or docetaxel) against various
types of cancers (colorectal, head and neck and prostate)
[32,33]. In mice bearing human colorectal cancer xeno-
grafts (HCT-8), combination treatment of MSC and iri-
notecan resulted in complete tumor regression (100%
CR) that was not observed with each drug alone (30%
CR) [32]. Sequential combination of MSeA and doce-
taxel resulted in synergy enhancing docetaxel-induced
cell death in CaP [33]. Multiple mechanisms of the
synergy between selenium and other chemotherapeutic
agents are proposed. Selenium (Se) is an essential ele-
ment that possesses antioxidant properties in a form of
selenoproteins protecting cells from harmful free radi-
cals [34-36]. The effect of selenium on b-catenin has yet
to be investigated.
This study is designed mainly to determine if b-cate-
nin is a target of MSeA in CRC, HNSCC and CaP can-
cers; and to evaluate the role of GSK-3b in the
degradation of b-catenin and if such an effect is asso-
ciated with enhanced cytotoxicity of anticancer drugs.
Results
Inhibition of b-catenin by MSeA is concentration, time
and tumor type dependent
To evaluate the effect of MSeA on the expression of
b-catenin, various tumor cell types were treated with
multiple time and doses of MSeA. In all treated cells,
MSeA decreased the expression of b-catenin in dose
and time dependent manners (Figure 1). The data in
Figure 1 indicate that the down regulation of b-catenin
is MSeA concentration dependent. In CRC cells (HCT-8
and HT-29), 24 h treatment with 5 μM resulted in com-
pletely depletion of b-catenin. In contrast, in HNSCC
cells (FaDu and A253), the decrease in b-catenin levels
in FaDu cells was achieved with lower concentrations of
MSeA (0.5 μM) than in A253 (5 μM) (Figure 1A). In
the androgen-independent CaP cells (PC3 and C42),
inhibition of b-catenin by MSeA required a high con-
centration (5 μM) (Figure 1A). The kinetics of b-catenin
inhibition by MSeA appears to be tumor type depen-
dent, early in HCT-8, C42, HT-29 and PC3, and late
event in FaDu and A253 (Figure 1B).
MSeA inhibits b-catenin nuclear expression
To determine whether MSeA down regulates the activity
of b-catenin, nuclear and cytoplasmic extracts of colorec-
tal cancer cells were tested for the level of b-catenin
before and after MSeA treatment. The data in Figure 2A
indicate that b-catenin is predominantly expressed in the
nucleus of untreated CRC cells (HCT-8 and HT-29) indi-
cating activation of b-catenin. Treatments with MSeA
resulted in inhibition of nuclear expression of b-catenin
(Figure 2B). These data suggest that MSeA down regu-
lates b-catenin activity through inhibiting its nuclear
expression.
Inhibition of b-catenin is due to enhanced degradation
To determine whether the observed down regulation of
b-catenin by MSeA results from inhibition of its synth-
esis or from increased degradation, cells were treated
with MSeA and cycloheximide (an inhibitor of de novo
protein synthesis [37]) alone and in combination.
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Figure 1 MSeA effect on intracellular expression of b-catenin. Six human cancer cell lines including 2 colorectal (HT-29 and HCT-8), 2 head
and neck (FaDu and A253) and 2 prostate (PC3 and C42) were treated with various doses of MSeA (panel 1A) and various times (panel 1B).
Western blot analyses show that MSeA inhibits intracellular level of b-catenin in dose and time dependent manners.
Saifo et al. Molecular Cancer 2010, 9:310
http://www.molecular-cancer.com/content/9/1/310
Page 3 of 11
Treatments for up to 30 minutes did not affect the
expression level of b-catenin (Figure 3A). However,
b-catenin is down regulated after 24 h treatment with
MSeA alone and in combination with cycloheximide
(Figure 3B). These data suggest that the inhibition of
b-catenin by MSeA is the result of increased degradation.
The role of GSK-3b in b-catenin degradation is cell type
dependent
To determine the mechanism of b-catenin degradation
by MSeA, the role of GSK-3b was evaluated in HT-29
and HCT-8 (Figure 4). Treatments with MSeA had no
significant effect on the level of total GSK-3b (in HT-29
or HCT-8) and on the level of phosphorylated GSK-3b
in HCT-8. In contrast, phosphorylated GSK-3b was sig-
nificantly decreased in HT-29 (Figure 4A).
To evaluate further the role of GSK-3b, cells were
treated with lithium chloride (LiCl) alone (GSK-3b inhi-
bitor [38]) and in combination with MSeA. Treatment
with LiCl increased the level of phosphorylated GSK-3b
in both cell lines indicating inhibition of GSK-3b (Figure
4B). Combination of MSeA with various doses of LiCl
resulted in reversing the down regulation of b-catenin
in HT-29 cells but not HCT-8 by MSeA (Figure 4B).
Data in Figure 4 demonstrated that the inhibition of
b-catenin by MSeA is GSK-3b phosphorylation depen-
dent in HT-29 but independent in HCT-8.
The effect of MSeA in combination therapy on the level
and activity of b-catenin
To determine whether MSeA in combination with a che-
motherapeutic agent would affect b-catenin expression
and activity, cells were treated with MSeA ± chemothera-
peutic agent and analyzed for total and nuclear b-catenin
expression. The data in Figure 5A indicate that MSeA
inhibited b-catenin expression in all cell lines but neither
7-Ethyl-10-Hydroxycamptothecin (SN-38, the active meta-
bolite of irinotecan) nor docetaxel alone had an effect on
the b-catenin levels. Adding SN-38 or docetaxel to MSeA
did not interfere with selenium inhibition of b-catenin.
The combination of MSeA/SN-38 resulted in even more
observed inhibition of total b-catenin when compared
with MSeA alone in HT-29, HCT-8 and FaDu cells. In
CaP cells, MSeA alone and in combination with docetaxel
have similar inhibitory effect on the expression of
Figure 2 MSeA effect on the nuclear expression of b-catenin.
Colorectal cancer cells express a high-level of nuclear b-catenin
indicating activation (panel 2A). Treatment with MSeA results in
inhibition of the nuclear expression of b-catenin indicating
suppression of the active form of b-catenin (panel 2B). Figure 3 MSeA inhibition of b-catenin is due to degradation.
Colorectal cancer cells were treated with a protein synthesis
inhibitor, cycloheximide (CHX) and MSeA alone or in combination
for various times up to 30 minutes (panel 3A) and for 24 h (panel
3B). No early changes in the b-catenin level were observed (panel
3A). However, 24 h combination treatment with CHX/MSeA resulted
in same inhibition after MSeA alone (panel 3B).
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b-catenin (Figure 5A). To determine whether the inhibi-
tion of b-catenin by MSeA in combination with SN-38 is
due to inhibition of the nuclear expression, nuclear
extracts of CRC cells were treated with MSeA alone and
in combination with SN-38 and evaluated for the level of
b-catenin. The combination treatment of MSeA/SN-38
resulted in down regulation of the nuclear expression of
b-catenin in HT-29 and HCT-8 cells (Figure 5B). These
results indicate that the activity of b-catenin is decreased
after the combination therapy.
Figure 4 The role of GSK-3b in degradation of b-catenin. Colorectal cancer cells were treated with various doses of MSeA alone (panel 4A)
or in combination with GSK-3b inhibitor, Lithium Chloride (LiCl, panel 4B). The level of total GSK-3b, p-GSK-3b and b-catenin were determined
using western blots. Treatment with MSeA alone had no effect on total GSK-3b but decreased the level of p-GSK-3b only in HT-29 (panel 4A).
Treatments with LiCl increased the level of p-GSK-3b (inactive form of GSK-3b) but had no effect on b-catenin expression (panel 4B).
Combination treatment of LiCl/MSeA continued to inhibit expression of b-catenin only in HCT-8 (panel 4A)
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The inhibition of b-catenin expression by ShRNA or MSeA
is associated with enhancement of drug-induced growth
inhibition of tumor cell
To determine whether inhibition of b-catenin can be
correlated with enhanced efficacy of chemotherapy,
b-catenin in tumor cells was knockdown by specific
ShRNA. Two b-catenin ShRNA tranfectant clones
(HCT-8RH7 and HCT-8RF4) that demonstrated inhibi-
tion of b-catenin expression when compared with
scrambled control (HCT-8SC) and wild type (HCT-
8WT) were selected for further testing (Figure 6A).
To evaluate the effect of silencing b-catenin on cell
growth, HCT-8WT, HCT-8SC and HCT-8R (HCT-
8RH7 and HCT-8RF4) transfectants were treated with
various classes of chemotherapeutic agents. Treatments
with 0.5 μM of SN-38 were more effective (p < 0.05)
against HCT-8R (~50% cell growth inhibition) when
compared with all other groups (15% cell growth
Figure 5 Combination treatment effect on the expression of b-catenin. Cancer cells (panel 5A) and nuclear extraction of colorectal cancer
cells (panel 5B) were treated with MSeA, SN-38 and docetaxel alone or in combination. Expression of b-catenin was determined using western
blots. Combination treatments of MSeA/SN-38 continued to decrease expression of b-catenin when compared with all other groups.
Combination treatments of MSeA/docetaxel did not reverse the inhibitory effect of MSeA alone on expression of b-catenin (panel 5A). The active
form (nuclear expression) of b-catenin was inhibited by the combination treatment of MSeA/SN-38 when compared with other group (panel 5B).
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Figure 6 The effect of various drug treatments on cell growth and proliferation in b-catenin knockout cells. Beta-catenin was silenced in
colorectal cancer cells (HCT-8, panel 6A). HCT-8 wild type cells (HCT-8WT), scramble controls (HCT-8SC) and 2 b-catenin knockout clones (HCT-
8RH7 and HCT-8RF4) were tested. Expression of b-catenin was significantly lower in HCT-8RH1 and HCT-8RF4 when compared with all other
groups (panel 6A). Cancer cell growth and proliferation were determined in HCT-8WT, HCT-8SC, HCT-8RH7 and HCT-8RF4 after treatment with
various doses of SN-38, docetaxel, paclitaxel, oxaliplatin, 5-FU and topotecan using SRB assay. HCT-8RH7 and HCT-RF4 cells were significantly
more sensitive to various drug treatments when compared with HCT-8WT and HCT-8SC (panel 6B). * denotes a p value of less than 0.05 when
compared with all other groups.
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inhibition in HCT-8SC or HCT-8WT, Figure 6B). Other
doses of SN-38 resulted in similar patterns of inhibition
of cell growth (Figure 6B). In similar fashion, treatments
with various doses of docetaxel, paclitaxel, oxaliplatin, 5-
FU and topotecan significantly enhanced efficacy against
cell growth of HCT-8RH7 and HCT-8RF4 when com-
pared with all other groups of HCT-8SC or HCT-8WT
(Figure 6B).
To confirm further that inhibition of b-catenin is asso-
ciated with enhanced cytotoxicity of anticancer drugs,
tumor cells were treated with MSeA alone and in com-
bination with SN-38 and the results were correlated
with the levels of b-catenin (table 1). The data in table 1
demonstrated a relationship between enhanced cytotoxi-
city of SN-38 and inhibition of b-catenin by MSeA or
ShRNA. Thus, these data support the initial hypothesis
that inhibition of b-catenin by MSeA is a critical deter-
minant of drug response.
Discussion
Beta-catenin oncogonic protein is widely expressed in
many human malignancies [1] including HNSCC [2-4],
CaP [5,6] and CRC [8-10]. Beta-catenin is involved in
cell growth [22-24], adhesion [11] and stemness [26,27].
Beta-catenin is found in multiple cellular locations
including intracellular membrane, cytoplasm and
nucleus. The nuclear accumulation of b-catenin indi-
cates the activation of its oncogenic form that stimulates
transcription factors and genes [22-24] leading to
enhanced tumor cell growth and poor prognosis [25].
The hypothesis of this study is that b-catenin is a target
of MSeA and its inhibition would translate into
enhanced drug effect. Our results (Figure 1) established
that MSeA is a potent inhibitor of b-catenin in various
cancer types. This broad inhibitory effect of MSeA on
the expression of b-catenin is pivotal for explaining the
established synergy between selenium and various che-
motherapeutic agents against multiple cancers.
The data in Figure 2 demonstrate that the inhibition
of b-catenin level after MSeA is due to the inhibition of
the active form of b-catenin in the nucleus. Thus, these
data indicate that pharmacologic doses of MSeA offer
effective inhibition of b-catenin activation.
Recent findings by Zhang et al demonstrate that sele-
nium effect against esophageal squamous cell carcinoma
is correlated with its inhibition on b-catenin/TCF path-
way [39]. Our results confirm this finding in various
human cancers and prove that the decreased level of
b-catenin is associated with enhanced efficacy of various
classes of chemotherapy. Thus, indicating the impor-
tance of b-catenin inhibition in drug response.
To determine whether the inhibition of b-catenin is
due to a decrease in synthesis or an increase in degrada-
tion, de novo protein synthesis was inhibited using CHX
in the presence and absences of MSeA. The data in
Figure 3 indicate that MSeA inhibition of b-catenin is
due to increase in degradation but not decrease in synth-
esis in both CRC cells (HT-29 and HCT-8). Many studies
have showed that cytoplasm b-catenin is degraded by an
axin/GSK-3b/APC complex [12-14] and the degradation
is a GSK-3b phosphorylation dependent process [14,15].
The degradation of the cytoplasm b-catenin prevents its
accumulation and translocation into the nucleus. Data in
Figure 4 demonstrated that the inhibition of b-catenin by
MSeA is GSK-3b dependent phosphorylation in HT-29
but independent in HCT-8. The GSK-3b independent
degradation of b-catenin is a novel finding in HCT-8
cells and indicates that the MSeA effect involves other
signaling pathways than Wnt/b-catenin, which will be
investigated in future studies.
In preclinical models, sequential combination treat-
ment of selenium compounds (MSC, SLM or MSeA)
and various chemotherapeutic agents (SN-38 or doce-
taxel) were proven synergistic against various cancers
including HNSCC, CRC and CaP [32,33]. Studies were
carried out to determine whether the combination treat-
ment of MSeA and chemotherapeutic agents affect
b-catenin level in those cell lines. Our results in Figure 5
showed that treatment with MSeA in combination with
SN-38 or docetaxel down regulated the total and the
nuclear b-catenin. These results confirm that the
chemotherapeutic agent did not interfere with selenium
inhibition of the level and activity of b-catenin. However,
neither SN-38 nor docetaxel alone affect the expression
level of b-catenin (Figure 5).
To determine that inhibition of b-catenin by MSeA
will translate into enhanced drug-cytotoxicity, cells
knocked down b-catenin by ShRNA were more sensitive
to growth inhibition by SN-38 than wild type. Collec-
tively, this study indicates that the decreased level of
b-catenin is associated with enhancement of drug
induced inhibition of cell growth. (table 1).
Further, the data in Figure 6 indicate that silencing
b-catenin increases the cytotoxicity of various chemother-
apeutic agents. The efficacy of SN-38, docetaxel, paclitaxel,
Table 1 The inhibition of b-catenin expression by ShRNA
or MSeA is associated with drug-induced growth
inhibition of tumor cells
HCT-8 cell line % cell growth inhibition Beta-catenin expression
Control 0% ++++/strong
MSeA (1 μM) ~50% ++/weak
SN-38(0.7 μM) ~20% ++++/strong
MSeA+SN-38 >95% +/very weak
ShRNA 0% ++/weak
ShRNA+SN38 ~70% +/very weak
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oxaliplatin, 5-FU and topotecan was significantly
increased in HCT-8R when compared with control groups
(Figure 6B).
Conclusions
These results support the hypothesis that b-catenin is a
target of MSeA and its inhibition results in enhanced
drug-cytotoxicity in multiple cancers. Degradation of
b-catenin by GSK-3b is not a general mechanism but it
is cell type dependent.
Although Selenium is a multi-target agent [32,33,40],
inhibition of b-catenin is a critical determinant of drug
response. These preclinical results provided the rationale
for validation of this new and innovative approach in a
clinical setting.
Materials and methods
Cell lines and drugs
Human cancer cell lines of colorectal (HCT-8 and HT-
29), head and neck (FaDu and A253) and prostate (PC3
and C42) were purchased from American type cell cul-
ture (ATCC, Manassas, VA) and maintained in RPMI
1640 with 10% fetal bovine serum (FBS). The cell lines
were tested regularly using Stratogene’s mycoplasma
plus PCR Primer set (La Jolla, CA) and they were free
from Mycoplasma. SN-38, docetaxel, 5-FU, paclitaxel,
oxaliplatin, lithium chloride (LiCl) and cycloheximide
(CHX) were purchased from Sigma Aldrich (St. Louis,
MO). MSeA (CH3SeO2H) was purchased from Phar-
maSe Inc. (Lubbock, TX). Toptecan was obtained from
GlaxoSmithKline (Durham, NC). Puromycin dihy-
drochloride, plasmid transfection medium and transfec-
tion reagents were purchased from Santa Cruz
biotechnology Inc. (Santa Cruz, CA).
Schedules and drug doses
Cells were treated with various doses of MSeA (0.05,
0.1, 0.5, 1, 5 and 10 μM) for various times (2, 4, 6, 8, 16
and 24 h). MSeA and SN-38 or docetaxel were given
alone or in sequential combination. In sequential combi-
nation, 2 h treatments with SN-38 (0.7, 1.3, 0.07 and 0.3
μM against HCT-8, HT-29, FaDu and A253 respec-
tively) or docetaxel (2 nM against PC3 and C42) started
22 h after treatment with MSeA (1 or 5 μM). HCT-8
parental and b-catenin knockout cells were treated with
SN-38 (2 h), docetaxel (2 h), paclitaxel (24 h), oxaliplatin
(24 h), 5-FU (24 h) and topotecan (2 h) using various
doses. The doses were for SN-38 (0.5, 1 and 5 μM), for
docetaxel (0.05, 0.1 and 0.5 μM), for paclitaxel (0.5, 1
and 5 μM), for oxaliplatin (1 and 5 μM), for 5-FU (50,
100 and 500 μM) and for topotecan (0.5 and 1 μM).
LiCl was applied for 24 h in multiple doses (0.5, 1, 5,
10, 20 and 25 mM) alone or in combination with MSeA
(5 μM).
Cycloheximide (CHX) was applied for 5, 10, 20, 30
minutes and 24 hours at a nontoxic concentration of
100 μM alone or in combination with MSeA (5 μM).
Puromycin dihydrochloride was used at concentration of
20 μM for clones’ selection.
Preparation of cytoplasm and nuclear extract
Cytoplasm and nuclear extracts were prepared as pre-
viously described [41]. Briefly, to obtain cytoplasm
extract, untreated and treated HCT-8 cells were har-
vested and suspended in lysis buffer (0.08 M KCl, 35
mM HEPES, pH 7.4, 5 mM potassium phosphate, pH
7.4, 5 mM MgCl2, 25 mM CaCl2, 0.15 M sucrose, 2 mM
PMSF, 8 mM dithiothreitol). After overnight storage at
-80°C, cells were passed through a 28-gauge needle, cen-
trifuged and the supernatant collected to represent the
cytoplasm extract. The remaining pellet was re-sus-
pended in lysis buffer, sonicated, centrifuged and the
supernatant collected to represent the nuclear extract.
Silencing the expression of b-catenin
HCT-8 cells were utilized to generate a stable transfec-
tion using small hairpin b-catenin RNA (b-catenin
ShRNA) purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). Transfection was carried out follow-
ing the manufacture’s instructions. Briefly, HCT-8 cells
were plated 5 × 105 cells/well (6-well plate) one day
before the transfection. A well with 70-80% cells conflu-
ence was transfected with control shRNA Plasmid-A (a
negative control) that encodes a scrambled shRNA
sequence that does not inhibit b-catenin to generate
HCT-8 scrambled control (HCT-8SC). Another well
with the same cells confluence, was transfected with b-
catenin shRNA plasmid DNA, a b-catenin-specific lenti-
viral vector plasmid to knock down expression and gen-
erate HCT-8 recombinant clones (HCT-8R). Clones of
stable transfectants were selected using 20 μM of puro-
mycin dihydrochloride. After selection, 10 individual
clones were evaluated using western blots and the 2
clones (HCT-8RH7 and HCT-8RF4) that demonstrated
the most effect of survivin suppression were selected for
further studies.
Western blots analyses
Western blots were performed as described previously
[33] to determine the effects on the intracellular protein
levels. Briefly, untreated and treated cells were collected
and digested using RIPA buffer (1 M Tris, 1 M NaCl,
Triton X-100 and distilled water) with fresh protease
inhibitor cocktail. Protein level was measured using Bio-
Rad DC protein assay and a synergy HT spectrophot-
ometer (BioTek Instruments, Winooski, VT). Equal
amount of protein (50 μg) was loaded on 4-20% SDS-
PAGE. After transfer, nitrocellulose membrane was
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rinsed with PBS-T, blocked with 5% milk and hybridized
with the selected antibody. The following primary anti-
bodies were used: anti-b-catenin, anti-GSK-3b (BD Bios-
ciences, San Jose, CA) and anti-p-GSK-3b (cell signaling
technology, Danvers, MA). The following secondary
antibodies were used: goat anti-mouse IgG and goat
anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA). After incubation with the primary and secondary
antibodies, membrane was rinsed and incubated with
chemilluminescence or enhanced chemilluminescence
and developed using Kodak X-OMAT 2000A (First
Source Inc., Rochester, NY). Anti-b-actin (Sigma
Aldrich, St. Louis, MO) was used as loading controls.
Cell growth assay
Cell growth was evaluated using sulforhodlamine B
(SRB) assay as previously described and performed [33].
Briefly, after drug treatment, HCT-8WT, HCT-8SC and
HCT-8RH7 and HCT-8RF4 cells were incubated in a
drug-free medium for 5 days, fixed, washed and stained
with SRB dye. The optical density of bound dye was
measured at 570 nm using synergy HT multi-mode
microplate reader (BioTek Instruments, Winooski, VT).
Statistical analyses
Each experiment has been repeated at least 3 times.
Values were presented as the mean plus or minus stan-
dard deviation. Statistical analyses were performed com-
paring all treatments groups using unpaired t-student
test. Significant difference between groups was noted
when the p value was less than 0.05.
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